Revitope Oncology

REV-500 RD solid tumors, REV-600 RD solid tumors, REV-200 RD solid tumors, REV-300 RD solid tumors

Revitope Oncology is advancing precision cancer immunotherapies to safely and effectively treat more cancers. Many potent immunotherapies have been identified, however reducing off-target killing of healthy cells is imperative to identify safe therapeutics. Revitope’s strategy resolves this by using immunotherapies composed of two bispecific antibodies - each molecule binds a distinct tumor antigen and both are required to bind a cell for the immune system to be recruited. Revitope is using this PrecisionGATETM technology to establish their pipeline of novel therapies for solid cancers, currently in preclinical stages.

Jobs: